Abstract
Generalized Pustular Psoriasis (GPP) is a recurrent dermatological condition characterized by widespread erythematous plaques, scaling, and sterile pustules. Notably, in a subset of patients, these lesions manifest exclusively in localized areas. We report a case where abrocitinib was used to treat the localized type of GPP, achieving relatively good clinical efficacy and without obvious side effects. To date, there are no published reports on the use of abrocitinib for GPP treatment, either domestically or internationally, making this case a valuable reference for clinicians and researchers.